Suppr超能文献

指甲银屑病及其治疗对生活质量的影响:一项系统评价。

The Impact of Nail Psoriasis and Treatment on Quality of Life: A Systematic Review.

作者信息

Stewart Claire R, Algu Leah, Kamran Rakhshan, Leveille Cameron F, Abid Khizar, Rae Charlene, Lipner Shari R

机构信息

Weill Cornell Medical College, New York, New York, USA.

Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.

出版信息

Skin Appendage Disord. 2021 Feb;7(2):83-89. doi: 10.1159/000512688. Epub 2021 Jan 22.

Abstract

At least 80% of patients with psoriasis will have nail involvement during their lifetimes. Understanding quality of life (QoL) impact of this condition and associated treatments is of utmost importance. Study objectives were to review the available literature describing patient-reported QoL outcomes in nail psoriasis and relationship with disease severity and treatment. A literature search was performed for English-language articles published prior to August 1, 2020. Articles were included in the review if primary data and validated patient-reported outcome measures assessing QoL were presented, and nail involvement was specifically examined. Fifteen studies were included in the final analysis. Patients with nail psoriasis had higher Psoriasis Area Severity Index and Dermatology Life Quality Index scores than those with psoriasis without nail involvement. The largest percent improvement in QoL score was associated with adalimumab. Studies investigating topicals, intralesionals, and systemic treatments were excluded since only biologic studies utilized validated patient-reported outcome measures. This review affirms that nail psoriasis is physically and emotionally distressing, warranting prompt treatment. Increased efforts are needed to address the impact of treatment on patient QoL using validated outcome measures that assess cosmetic, physical, and social problems.

摘要

至少80%的银屑病患者在其一生中会出现指甲受累情况。了解这种疾病及其相关治疗对生活质量(QoL)的影响至关重要。研究目的是回顾现有文献,描述指甲银屑病患者报告的生活质量结果以及与疾病严重程度和治疗的关系。对2020年8月1日前发表的英文文章进行了文献检索。如果文章呈现了原始数据以及经过验证的评估生活质量的患者报告结局指标,并且专门研究了指甲受累情况,则纳入该综述。最终分析纳入了15项研究。与无指甲受累的银屑病患者相比,指甲银屑病患者的银屑病面积和严重程度指数以及皮肤病生活质量指数得分更高。生活质量得分改善百分比最大的与阿达木单抗相关。由于只有生物制剂研究使用了经过验证的患者报告结局指标,因此排除了研究局部用药、皮损内注射和全身治疗的研究。该综述证实指甲银屑病在身体和情感上令人痛苦,需要及时治疗。需要加大力度,使用评估美容、身体和社会问题的经过验证的结局指标来解决治疗对患者生活质量的影响。

相似文献

1
The Impact of Nail Psoriasis and Treatment on Quality of Life: A Systematic Review.
Skin Appendage Disord. 2021 Feb;7(2):83-89. doi: 10.1159/000512688. Epub 2021 Jan 22.
2
Patient Satisfaction with Treatment for Onychocryptosis: A Systematic Review.
Skin Appendage Disord. 2020 Sep;6(5):272-279. doi: 10.1159/000508927. Epub 2020 Jul 17.
3
Interventions for nail psoriasis.
Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD007633. doi: 10.1002/14651858.CD007633.pub2.
4
Nail Psoriasis, the unknown burden of disease.
J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1690-5. doi: 10.1111/jdv.12368. Epub 2014 Jan 15.
7
Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study.
J Eur Acad Dermatol Venereol. 2015 Feb;29(2):353-360. doi: 10.1111/jdv.12553. Epub 2014 May 21.
8
Efficacy of Systemic Treatments of Nail Psoriasis: A Systemic Literature Review and Meta-Analysis.
Front Med (Lausanne). 2021 Feb 10;8:620562. doi: 10.3389/fmed.2021.620562. eCollection 2021.
9
Nail psoriasis as a severity indicator: results from the PsoReal study.
Patient Relat Outcome Meas. 2011 Jul;2:1-6. doi: 10.2147/PROM.S14861. Epub 2010 Dec 22.
10
Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients.
JAMA Dermatol. 2020 Jan 1;156(1):72-78. doi: 10.1001/jamadermatol.2019.3717.

引用本文的文献

1
Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 25. doi: 10.1007/s00210-025-04334-1.
2
Clinical Trials in Nail Psoriasis: Cross-Sectional Analysis of the Current State of Research.
Skin Appendage Disord. 2025 Jun;11(3):232-244. doi: 10.1159/000542568. Epub 2024 Nov 12.
3
Unveiling Psoriasis: Delving into Pathogenesis, Treatment Breakthroughs, and Patent Trends.
Recent Adv Inflamm Allergy Drug Discov. 2025;19(1):31-45. doi: 10.2174/0127722708307214240628042627.
5
Inflammatory Nail Disorders in Skin of Color: A Systematic Review of Clinical and Onychoscopic Manifestations.
Int J Dermatol. 2025 Jun;64(6):1013-1020. doi: 10.1111/ijd.17680. Epub 2025 Feb 11.
6
Botulinum toxin injection shows promise in nail psoriasis: A comparative randomized controlled trial.
JAAD Int. 2024 Apr 30;16:105-111. doi: 10.1016/j.jdin.2024.03.021. eCollection 2024 Sep.
7
Nails in older adults.
Ann Med. 2024 Dec;56(1):2336989. doi: 10.1080/07853890.2024.2336989. Epub 2024 May 13.
8
Development and Validation of a Patient-Reported Outcome Measure for Fingernail and Toenail Conditions: The NAIL-Q.
Clin Cosmet Investig Dermatol. 2023 Oct 27;16:3091-3105. doi: 10.2147/CCID.S429120. eCollection 2023.
9
Brodalumab in the Treatment of Plaque Psoriasis Localized in Difficult-to-Treat Areas: A Narrative Review.
Dermatol Pract Concept. 2023 Jul 1;13(3):e2023245. doi: 10.5826/dpc.1303a245.
10
Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review.
Am J Clin Dermatol. 2023 Sep;24(5):695-720. doi: 10.1007/s40257-023-00786-4. Epub 2023 May 20.

本文引用的文献

1
Efficacy of Adalimumab for Nail Psoriasis During 24 Months of Continuous Therapy.
Acta Derm Venereol. 2020 Jul 28;100(14):adv00214. doi: 10.2340/00015555-3545.
2
Psoriasis causes as much disability as other major medical diseases.
J Am Acad Dermatol. 2020 Jan;82(1):256-257. doi: 10.1016/j.jaad.2018.07.059.
6
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
J Am Acad Dermatol. 2018 Jan;78(1):90-99.e1. doi: 10.1016/j.jaad.2017.08.029. Epub 2017 Oct 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验